Trial Profile
A Phase II of AT-101 in Combination with Docetaxel in Patients with Recurrent, Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2012
Price :
$35
*
At a glance
- Drugs AT 101 (Primary) ; Docetaxel
- Indications Head and neck cancer
- Focus Therapeutic Use
- 10 Feb 2012 New trial record